OTU deubiquitinase 7BGenealiases: CEZANNE · ZA20D1
Q-omics provides the consensus-scored OTUD7B profile across patient tissues and cancer cell-line models. OTUD7B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OTUD7B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, OTUD7B RNA expression shows 20,501 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where OTUD7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTUD7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTUD7B survival associations across molecular data types. OTUD7B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTUD7B RNA expression–survival associations across cancer types. High OTUD7B expression shows unfavorable associations in ACC, KICH, LGG and LIHC, but favorable associations in KIRC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OTUD7B RNA expression.
This table summarizes OTUD7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for OTUD7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTUD7B shows lower tumor expression in KICH and COAD and higher tumor expression in HNSC, LIHC, BRCA and KIRP. The HNSC box plot shows higher OTUD7B RNA expression in tumor versus normal tissue (log2 FC = +0.634, t-test p < 0.001).
This table shows molecular features associated with OTUD7B in patient tissues and cancer cell lines. In patient samples, OTUD7B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, OTUD7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
